BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cemiplimab: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Regeneron Pharmaceuticals, Vyriad, Inc., OncoResponse, Inc., EMD Serono Research & Development Institute, Inc., Sensei Biotherapeutics, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-15 est. | P3 | Regeneron Pharmaceuticals REGN | NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has | Melanoma | active not recruiting | 1564 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | active not recruiting | 548 |
| 2026-11-02 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Melanoma | active not recruiting | 151 |
| 2026-10 est. | P2 | Vyriad, Inc. | NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer | active not recruiting | 87 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08-01 est. | P1/P2 | OncoResponse, Inc. | NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanom | recruiting | 168 |
| 2026-07-15 | P1/P2 | EMD Serono Research & Development Institute, Inc. | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Non-Small Cell Lung Cancer | completed | 61 |
| 2026-06-08 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squ | Cutaneous Squamous Cell Carcinoma | withdrawn | |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.